Mannkind (MNKD) Drug/indication: Afrezza for diabetes Approval decision date: Dec. 29, 2010 Recent stock performance: At $5.87, stock has lost almost half its value since March. This is the second review cycle for Afrezza, a small, inhaled insulin device for diabetes.
--Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.